Celltrion Inc (068270)
Korea Stock Exchange · Korea · prices in KRW · close of 22 Oct 2026
Key indicators
| Last close | KRW 194,300.00 |
|---|---|
| 52-week range | 158,500.00 – 251,000.02 |
| Return, 1 month / 3 months | +8.9% / +14.2% |
| Return, 1 year / 3 years | +14.9% / +58.4% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 41.1% |
| Worst drawdown (1 year) | -32.6% |
| Average daily value traded | 103,205.36M KRW |
| Dividend yield | 0.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Celltrion is a biopharmaceutical company based in South Korea that develops and manufactures biologic medicines, chiefly biosimilars of antibody-based treatments used in immunology and oncology. It produces these medicines at its own facilities and supplies them to healthcare providers and partners in markets around the world. The company also carries out research and development work on new biologic products and works with international pharmaceutical partners to bring its medicines to patients.
On this site Celltrion Inc appears as a stock on the Korea Stock Exchange (Korea), code 068270, with prices in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Celltrion Inc (068270) trades on the Korea Stock Exchange in Korea. It last closed at KRW 194,300.00 on 22 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 60 of 934 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.9% and over the last three months it rose 14.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Korea Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 80 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 2.5% | ||
| From 52-week high | -21.8% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 14.2% | ||
| 6-month return | 0.0% | ||
| 12-month return, skipping the last month | 5.6% | ||
| Stability (higher is calmer) | 70 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 41.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -32.6% | ||
| Liquidity | 97 · Strong | Trades actively. | |
| Average daily value traded | 103,205.36M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 27 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.4% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +6.7% |
|---|---|
| 1 month | +8.9% |
| 3 months | +14.2% |
| 6 months | +0.0% |
| 1 year | +14.9% |
| 3 years | +58.4% |
| 5 years | +9.5% |
Signals
| 50-day / 200-day average | 187,626.00 / 189,589.92 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6,044.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 29 Dec 2025 | KRW 750.0000 |
| 27 Dec 2024 | KRW 750.0000 |
| 27 Dec 2023 | KRW 500.0000 |
| 28 Dec 2022 | KRW 390.0000 |
| 29 Dec 2021 | KRW 765.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Korea Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.